Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study

Autor: Köksal, I., Yilmaz, G., Parlak, M., Demirdal, T., Kinikli, S., Candan, M., Kaya, A., Akhan, S., Aydoǧdu, Ö., Turgut, Hüseyin, Gürbüz, Y., Daǧli, Ö., Gökal, A.A., Güner, R., Kuruüzüm, Z., Tarakçi, H., Beslen, N., Erdoǧan, S., Özdener, F., Duyar, E., Inan, D., Leblebicioǧlu, H., Sehmen, E., Yuluǧkural, Z., Namiduru, M., Kökoǧlu, Ö.F., Baykam, N., Ural, O., Bostanci, F., Kaya, S., Kiliç, S., Önlen, Y., Özdemir, D., Tabak, F., Yamazhan, T.
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Liver Cirrhosis
Male
Turkey
clinical evaluation
Biopsy
Hepacivirus
Turkey (republic)
FibroTest
aspartate aminotransferase
Liver Function Tests
middle aged
statistics and numerical data
APRI
liver fibrosis
Forns index
Fib-4
adult
clinical trial
Alanine Transaminase
biological marker
virology
aged
female
Liver
Area Under Curve
young adult
diagnostic value
Adolescent
area under the curve
alanine aminotransferase
disease classification
complication
Sensitivity and Specificity
Article
open study
blood
turkey (bird)
chronic hepatitis C
Humans
Non-invasive serum biomarkers
liver function test
human
procedures
Aspartate Aminotransferases
liver biopsy
Platelet Count
scoring system
Hepatitis C
Chronic

major clinical study
Chronic hepatitis C infection
human tissue
multicenter study
observational study
pathology
aspartate aminotransferase blood level
Biomarkers
Popis: Background/Aims: The hepatitis C virus (HCV) infection is important cause of chronic hepatitis. Liver biopsy is considered the gold standard for assessment of fibrosis but this procedure is an invasive procedure. We aimed to evaluate the diagnostic efficiency of non-invasive serum biomarkers, separately and in combinations, on liver fibrosis in treatment-naive chronic hepatitis C (CHC) patients. Materials and Methods: Two hundred and sixteen treatment-naive CHC patients were enrolled from 32 locations across Turkey in this open-labelled, non-interventional prospective observational study. FibroTest®, aspartate aminotransferase-to-platelet ratio index(APRI), aspartate aminotransferase and alanine aminotransferase ratio (AAR), fibrosis index based on four factors (FIB-4), Age-platelet(AP) index and Forns index were measured and compared with Metavir scores got from liver biopsies. Results: Data from 182 patients with baseline liver biopsy were suitable for analysis. One hundred and twenty patients (65.9%) had F0-F1 fibrosis and 62 patients (34.1%) had F2-F4 fibrosis. APRI 0.732 area under the curve(AUC) indicated advanced fibrosis with 69% sensitivity and 77% specificity. FIB-4 0.732 AUC and FibroTest 0.715 AUC indicated advanced fibrosis with 69% and 78.4% sensitivity, and 75% and 71.4% specificity, respectively. The combined use of tests also led to an increase in AUC and specificity. Combinations of FibroTest with APRI and/or FIB-4, and FIB-4 with APRI were optimal for the evaluation of liver fibrosis. Conclusion: Fibrotest, FIB-4, APRI, AP index and Forns index exhibit good diagnostic performance for determining liver fibrosis in CHC patients, and the use of at least two tests together will increase their diagnostic value still further. © Copyright 2018 by The Turkish Society of Gastroenterology.
Databáze: OpenAIRE